Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Overview of immune checkpoint inhibitors in gynecological cancer treatment
ID
Pirš, Boštjan
(
Avtor
),
ID
Škof, Erik
(
Avtor
),
ID
Smrkolj, Vladimir
(
Avtor
),
ID
Smrkolj, Špela
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(731,71 KB)
MD5: 3A16559924EAAE54BC5F454D5EB80E1B
URL - Izvorni URL, za dostop obiščite
https://www.mdpi.com/2072-6694/14/3/631
Galerija slik
Izvleček
In the last ten years, clinical oncology has been revolutionized by the introduction of oncological immunotherapy, mainly in the form of immune checkpoint inhibitors (ICIs) that transformed the standard of care of several advanced solid malignancies. Using ICIs for advanced gynecological cancers has yielded good results, especially for endometrial cancer. In ovarian or cervical cancer, combining ICIs with other established agents has shown some promise. Concurrently with the clinical development of ICIs, biomarkers that predict responses to such therapy have been discovered and used in clinical trials. The translation of these biomarkers to clinical practice was somewhat hampered by lacking assay standardization and non-comprehensive reporting of biomarker status in trials often performed on a small number of gynecological cancer patients. We can expect increased use of ICIs combined with other agents in gynecological cancer in the near future. This will create a need for reliable response prediction tools, which we believe will be based on biomarker, clinical, and tumor characteristics. In this article, we review the basic biology of ICIs and response prediction biomarkers, as well as the latest clinical trials that focus on subgroup effectiveness based on biomarker status in gynecological cancer patients.
Jezik:
Angleški jezik
Ključne besede:
immune check-point inhibitor
,
biomarker
,
endometrial cancer
,
ovarian cancer
,
uterine cervical cancer
,
vulvar cancer
,
treatment response prediction
Vrsta gradiva:
Članek v reviji
Tipologija:
1.02 - Pregledni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2022
Št. strani:
24 str.
Številčenje:
Vol. 14, iss. 3, art. 631
PID:
20.500.12556/RUL-137026
UDK:
618.1
ISSN pri članku:
2072-6694
DOI:
10.3390/cancers14030631
COBISS.SI-ID:
95979779
Datum objave v RUL:
30.05.2022
Število ogledov:
558
Število prenosov:
104
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Cancers
Skrajšan naslov:
Cancers
Založnik:
MDPI
ISSN:
2072-6694
COBISS.SI-ID:
517914137
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:
01.02.2022
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
ginekologija
,
rak endometrija
,
biomarkerji
,
rak jajcevodov
,
rak materničnega vratu
,
zdravljenje
Projekti
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
University Medical Centre Ljubljana
Številka projekta:
TP20210160
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj